KyungDong Pharm home
Prescription Medicines

Roxrin Tab.

Product Category
broad-spectrum antibiotics
Active Ingredients
roxithromycin
Appearance
white round tablet
Reimbursement Code
648100570
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength
1 tablet
- Active ingredient: Roxithromycin (KP) ----- 150mg (potency)
- Additives: Microcrystalline cellulose, titanium oxide, magnesium stearate, silicon dioxide, sodium starch glycolate, povidone, polyethylene glycol 6000, hypromellose 2910

2. Effectiveness
○ Effective bacterial species
Streptococcus, Streptococcus pneumoniae, Meningococcus, Neisseria gonorrhoeae, Bordetella whooping cough, Catharococcus, Diphtheria, Clostridium perfringens, Mycoplasma pneumoniae, Chlamydia trachomatis, Ureaplasma urealyticum, Legionella pneumophila, Campylobacter pylori, Campylobacter jejunum, Gardnerella vaginalis, Haemophilus influenzae, Staphylococcus aureus, cholera, psittacosis Chlamydia
○ Indications
- Respiratory infections such as pharyngitis, acute bronchitis, tonsillitis, bacterial pneumonia, and mycoplasma pneumonia
- Reproductive infections and sexually transmitted diseases, excluding infections caused by gonococci
- Otitis media, sinusitis
- Folliculitis, boils, furunculosis, carbuncles, erysipelas, cellulitis, lymphangitis, raw hands, purulent paronychia, subcutaneous abscess, hidradenitis, congestive acne, infectious atheroma
- To prevent infection in case of contact with a patient with meningococcal meningitis
- Pericoronitis, periodontitis

3. Dosage and dosage
Adults: As roxithromycin, take 150 mg (potency) orally twice a day before breakfast and dinner.
In case of pneumonia, 300 mg (titer) is administered once a day before breakfast.
Increase or decrease appropriately depending on age and symptoms.

4. Precautions for use
1. Warning
Severe blistering skin reactions such as Stevens-Jones syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis have been reported (see ‘3. Adverse Reactions’). If symptoms or signs of this severe blistering skin reaction (e.g. progressive skin rash such as blisters or mucosal damage) appear, administration should be discontinued.

2. Do not administer to the following patients
1) Patients with hypersensitivity to this drug or macrolide antibiotics
2) Patients taking terfenadine, astemizole, cisapride, or pimojit
3) Patients taking ergot alkaloids (ergotamine, dihydroergotamine-containing preparations) or mizolastine (may cause peripheral vasospasm, limb ischemia, and paresthesia).

3. Administer with caution to the following patients:
1) Patients with liver impairment
2) Elderly people
3) Be careful of cross-resistance when using in combination with other antibiotics (macrolide antibiotics, lincomycin, clindamycin, chloramphenicol).
4) Macrolide antibiotics, including this drug, may prolong the QT interval on electrocardiograms in some patients. Therefore, caution is required when administering this drug to patients with a congenitally prolonged QT interval, patients at risk for arrhythmia (e.g., uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia), or patients receiving Class IA or Class III antiarrhythmic drugs, astemizole, cisapride, or pimozit.
5) As is known with other macrolide antibiotics, this drug has the potential to worsen myasthenia gravis.

4. Adverse reactions
1) Shock (anaphylactic shock): In rare cases, shock may occur, so observe thoroughly and if abnormalities are identified, stop administration and treat appropriately.
2) Hypersensitivity reaction: Fever, sometimes rash, allergic skin reaction, and angioedema may occur. If these symptoms occur, discontinue administration.
3) Blood system: Occasionally, an increase in eosinophils, agranulocytosis, a decrease in white blood cells, and a decrease in platelets may occur.
4) Liver: Cholestatic or hepatocellular acute hepatitis (sometimes accompanied by jaundice) or elevations of AST, ALT, ALP, and serum bilirubin may occur.
5) Digestive system: Occasionally, loss of appetite, nausea, vomiting, stomach discomfort (indigestion), stomach pain, abdominal pain, abdominal bloating, diarrhea (sometimes accompanied by bleeding), pseudomembranous colitis, and loose stools may occur. In rare cases, severe colitis accompanied by bloody stool, such as hemorrhagic colitis, may occur. Therefore, if abdominal pain or frequent diarrhea occurs, take appropriate measures, such as immediately discontinuing administration. Symptoms of pancreatitis have been reported, but most patients were taking drugs in combination with drugs known to cause pancreatitis as an adverse reaction.
6) Disease caused by Clostridium difficile: Severe, persistent, or bloody diarrhea during or after treatment with this drug may be a symptom of pseudomembranous colitis. If pseudomembranous colitis is suspected, administration should be discontinued immediately.
7) Respiratory system: Bronchospasm, rarely interstitial pneumonia accompanied by fever, cough, difficulty breathing, abnormal chest
8) Nervous system: Drowsiness, rarely headache, dizziness, numbness of the tongue, paralysis, etc. may occur.
9) Sensory system: Like other macrolide antibiotics, taste abnormalities (including anosmia) and olfactory abnormalities (including loss of smell) may occur.
10) Skin: Skin reactions ranging from erythema multiforme, purpura, Stevens-Johnson syndrome, and toxic epidermal necrolysis may occur in rare cases. Acute generalized exanthematous pustulosis was reported in post-marketing surveillance.
11) Infection: As with other antibiotics, the use of this drug, especially if administered for a long period of time, may cause superinfection due to overgrowth of non-susceptible pathogens, so it is necessary to continuously evaluate the patient's condition. If superinfection occurs during treatment, appropriate measures should be taken.
12) Ears and inner ear: Temporary hearing loss, hearing impairment, dizziness
13) Eyes: Vision impairment, blurred vision, and bloodshot eyes were reported in post-marketing surveillance.
14) Others: General malaise, lethargy, palpitations, QT prolongation, ventricular tachycardia (including Torsades de pointes), arthralgia, epistaxis, menstrual abnormalities. Rarely, inflammation of the oral and vaginal mucosa (superinfection by Candida), hallucinations, and confusion have been reported.

5. General precautions
1) When using this drug, it is advisable to check susceptibility and administer only the minimum period necessary for treatment to prevent the development of resistant bacteria.
2) It is advisable not to administer to patients with impaired liver function, but if administration is unavoidable, liver function tests should be performed regularly to adjust the dose.
3) Since the amount excreted through the kidneys is small, there is no need to adjust the dose even in patients with renal failure.
4) Abnormalities in the epiphyseal cartilage layer were reported in young animals administered more than 10 times the normal therapeutic dose. Therefore, do not administer for more than 10 days at a dose of 5 to 8 mg per kg of body weight per day (limited to pediatric preparations).

6. Interaction
1) This drug inhibits the metabolism of various drugs metabolized in the liver and increases the blood concentration of the following drugs, which may rarely cause cardiovascular adverse reactions such as QT prolongation and ventricular arrhythmia (including torsades de pointes), so do not use it together: terfenadine, astemizole, cisapride, and pimogit.
2) Ergot alkaloids (ergotamine, dihydroergotamine): Do not administer together as acute ergot toxicity such as severe peripheral vasospasm, limb ischemia, and paresthesia may occur.
3) When administered in combination with theophylline, the blood concentration of theophylline may increase, causing symptoms of poisoning (nausea, vomiting).
4) Even when administered in combination with carbamazepine (200 mg once a day), the plasma concentration of carbamazepine does not change.
5) It may enhance the action of warfarin potassium and cause bleeding symptoms.
6) Cyclosporine: When administered in combination with this drug, the blood concentration of cyclosporine slightly increases, but there is no need to adjust the dose, but nephrotoxicity increases in patients with renal failure.
7) Midazolam: When administered in combination with this drug, the AUC can be increased in the midazolam concentration-time curve and the half-life of midazolam can be extended, making the effect stronger and longer lasting.
8) It may increase the absorption of digoxin and may result in overdose of digoxin.
9) Like other macrolide antibiotics, caution is required when administering this drug to patients receiving Class IA or Class III antiarrhythmic drugs.
10) Co-administration with mizolastine may cause peripheral vasospasm, limb ischemia, and paresthesia.
11) This drug is a weak CYP3A inhibitor. Drugs that are primarily metabolized by CYP3A exhibit a synergistic effect of approximately 2-fold or less with this drug. Caution is required when prescribed together with drugs metabolized by CYP3A (rifabutin, bromocriptine, etc.).

7. Administration to pregnant and lactating women
1) In animal experiments (rats), it has been reported that the incidence of external abnormalities and skeletal abnormalities in the fetus at about 80 times the clinical dose is higher than that in the control group, so it should be administered to pregnant women or women who may be pregnant only when the benefits of treatment are judged to outweigh the risks.
2) Since a small amount passes into breast milk, it is not recommended to be administered to nursing mothers, but if administration is unavoidable, stop breastfeeding.

8. Administration to elderly people
In elderly people, the half-life is prolonged. However, after repeated administration of 150 mg (titer) at 12-hour intervals, the peak blood concentration in normal conditions and the area under the blood concentration time curve (AUC) between administrations are the same as those in young patients, so there is no need to adjust the dose when administering to elderly patients.

9. Effects on operating and driving machinery
Dizziness, impaired vision, and blurred vision may affect the patient's ability to operate machinery or drive. (Refer to ‘3. Adverse Reactions’ section)

10. Precautions for storage and handling
1) Keep out of reach of children.
2) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
30 tablets/bottle, 100 tablets/bottle

7. Validity period
36 months from date of manufacture

Product Updates

Total 6items

No.Product NameDetailsDate of ChangeDownload
6Roxrin Tab.Roxrin Tablet (Precautions for use)2018.07.18PDFRoxlin Tablet.pdf
5Roxrin Tab.Roxrin Tablet (Precautions for use)2016.02.02PDF29_Roxrin Tablet.pdf
4Roxrin Tab.Roxrin Tablet (Precautions for use)2014.01.24HWPPrecautions for use_roxithromycin_others.hwp
3Roxrin Tab.Roxlin Tablet (Precautions for use)2007.09.12HWP9-3. Roxlin Tablet (Precautions for use) (2007.09.12).hwp
2Roxrin Tab.Roxlin Tablet (Precautions for use)2008.05.27HWP9-2. Roxlin Tablet (Precautions for use) (2008.05.27).hwp
1Roxrin Tab.Roxlin Tablet (Precautions for use)2008.07.21HWP9-1. Roxlin Tablet (Precautions for use) (2008.07.21).hwp